About Intercell
Intercell is a Healthcare company based in Vienna (Austria) founded in 1998 by Arunabh Varma. Vaccines for infectious diseases, including antigens and adjuvants, were developed. Intercell has raised $78.62 million across 2 funding rounds from investors including Global Life Science Ventures. Intercell has completed 1 acquisition, including Iomai Corporation. Its chief executive, as recorded, is Arunabh Varma. The company has since been acquired. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic.
Company details
Founded in 1998 in Vienna, Austria, Intercell focused on biotechnology within the infectious disease sector. Vaccines, antigens, and adjuvants were developed for various applications, with a Japanese encephalitis vaccine already marketed. Operations centered on research and production until the 2012 acquisition by Vivalis for 174 million, after which the combined entity was renamed Valneva.
- Headquarters Vienna, Austria
- Founders Arunabh Varma
- Stage Acquired
- SectorsHealthcare
- Website intercell.com
- Total Equity Funding$78.62M (USD)
in 2 rounds
- Latest Funding Round$44.98M (USD), Series B
Feb 2011
- InvestorsGlobal Life Science Ventures
& 1 more
- Investments & Acquisitions
Funding Insights of Intercell
Intercell has successfully raised a total of $78.62M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $44.98 million completed in February 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $78.62M
- Total Rounds 2
- Last Round Series B — $44.98M
- First Round $33.64M
(Jul 2003)
- Investors Count 1
All 2 funding rounds of Intercell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2011 | $44.98M | Series B | – | – | – |
| Jul 2003 | $33.64M | Series A | – | Global Life Science Ventures | – |
1 investors in total: 1 institutional.
Investors in Intercell
Intercell has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Global Life Science Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early & late stage life sciences focused VC firm funding companies in the US and Europe | global-life-science-ventures.com | Munich, Germany |
Investor details for Intercell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Intercell
2 people are tracked at Intercell (2 in leadership).
| Name | Role | Group |
|---|---|---|
Arunabh Varma | Founder & CEO | Leadership |
Thomas Lingelbach | CEO & President | Leadership |
Complete people profiles for Intercell
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Intercell
Intercell has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Iomai Corporation.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Vaccines and immune stimulants are developed via needle-free transcutaneous immunization. | iomai.com | Gaithersburg, United States | 1997 | May 2008 | $189M |
Complete acquisition details for Intercell
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Intercell
4 dated milestones of Intercell across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Intercell is founded.
- Funding First funding round of $33.6M.
- Acquisition Acquires Iomai Corporation.
- Funding Latest funding round, Series B, of $45.0M.
Web traffic of Intercell
Websites that share an audience with Intercell (intercell.com).
Websites whose visitors overlap most with Intercell. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| vaxgen.com | 100% | View details | |||
| seruminstitute.com | 100% | 63.5K | #656,121 | View details | |
testmed.com | testmed.com | 100% | – | ||
| argostherapeutics.com | 100% | View details | |||
| genphar.com | 100% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 27 similar websites and full traffic analytics for Intercell
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 27 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Intercell
Complete news archive for Intercell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intercell
Intercell was founded in 1998 and raised its 1st funding round 5 years after it was founded.
Intercell is headquartered in Vienna, Austria.
Arunabh Varma is the CEO of Intercell, as recorded in our data. They have also founded this company.
Intercell is a funded company, having raised a total of $78.62M across 2 funding rounds to date. The company's 1st funding round was a Series A of $33.64M, raised on Jul 2003.
Founded in 1998 in Vienna, Austria, Intercell focused on biotechnology within the infectious disease sector. Vaccines, antigens, and adjuvants were developed for various applications, with a Japanese encephalitis vaccine already marketed. Operations centered on research and production until the 2012 acquisition by Vivalis for 174 million, after which the combined entity was renamed Valneva.
Intercell has made 1 acquisition, including Iomai Corporation.
Intercell has 1 investor. Key investors include Global Life Science Ventures.